# US 11,897,965 B2 · Anti-Jagged1 antigen binding proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,897,965 B2
- Document ID: US11897965B2
- Status: Granted
- Kind: B2
- Application number: 17/672,889
- Filed: 2022-02-16
- Published: 2022-06-02
- Granted: 2024-02-13
- Earliest claimed: 2017-05-31
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Brian D. Bennett; Chadwick T. King; Jonathan Phillips
- Web page: https://patentgrep.com/patent/US11897965B2

## CPC

- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 37/00: Drugs for immunological or allergic disorders
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods of treating conditions related to lung disease using an antigen binding protein specific for the Jagged1 polypeptide are provided.

## Claims

### Claim 1

An isolated antigen binding protein that specifically binds to a human Jaggedl polypeptide; wherein the antigen binding protein is an antibody or a fragment thereof; wherein the antibody or a fragment thereof comprises a CDRL1, a CDRL2, a CDRL3, a CDRH1, a CDRH2, and a CDRH3; and wherein CDRL1 comprises SEQ ID NO:
98, CDRL2 comprises SEQ ID NO: 99, CDRL3 comprises SEQ ID NO: 100, CDRH1 comprises SEQ ID NO: 230, CDRH2 comprises SEQ ID NO: 231, and CDRH3 comprises SEQ ID NO: 232.

### Claim 2 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the human Jaggedl polypeptide has a sequence comprising SEQ ID NO: 353.

### Claim 3 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antigen binding protein is a monoclonal antibody, a polyclonal antibody, a recombinant antibody, a human antibody, a humanized antibody, a chimeric antibody, a multispecific antibody, or an antibody fragment thereof.

### Claim 4 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antibody fragment is a Fab fragment, a Fab′ fragment, or a F(ab′)2 fragment.

### Claim 5 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antigen binding protein is a human antibody.

### Claim 6 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antigen binding protein is a monoclonal antibody.

### Claim 7 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antigen binding protein is of the IgG1-, IgG2-, IgG3-, or IgG4-type.

### Claim 8 (depends on 7)

The isolated antigen binding protein of claim 7, wherein the antigen binding protein is of the IgG1- or the IgG2-type.

### Claim 9 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antigen binding protein is coupled to a labeling group.

### Claim 10 (depends on 9)

The isolated antigen binding protein of claim 9, wherein the antigen binding protein is coupled to the labeling group via a spacer arm.

### Claim 11 (depends on 9)

The isolated antigen binding protein of claim 9, wherein the labeling group is a radioisotope or radionuclide, a fluorescent group, an enzymatic group, a chemiluminescent group, a biotinyl group, or a predetermine polypeptide epitope recognized by a secondary reporter.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising at least one antibody or fragment thereof according to claim 1, and at least one pharmaceutically acceptable excipient.

### Claim 13 (depends on 12)

The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is formulated for intravenous administration, nebulization, or subcutaneous injection.

### Claim 14 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antigen binding protein is an scFv.

### Claim 15 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antigen binding protein is coupled to an effector group.

### Claim 16 (depends on 15)

The isolated antigen binding protein of claim 15, wherein the antigen binding protein is coupled to the effector group via a spacer arm.

### Claim 17 (depends on 15)

The isolated antigen binding protein of claim 15, wherein the effector group is a radioisotope or radionuclide, a toxin, a therapeutic group, or a chemotherapeutic group.

### Claim 18 (depends on 1)

The isolated antigen binding protein of claim 1, wherein the antibody or fragment thereof comprises a combination of a light chain variable region and a heavy chain variable region; and wherein the light chain variable region comprises SEQ ID NO: 7 and the heavy chain variable region comprises SEQ ID NO: 8.